Alterity Therapeutics Ltd has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- New data independently confirms safety profile of ATH434
- Pause in Trading
- Meeting with US FDA provides development path for ATH434
- Presentation on ATH434 to American Academy of Neurology
- Appendix 4C and Quarterly Update
Later from Alterity Therapeutics
- Company update on Annual Report 2020
- Alterity raises $35M in placement to institutional investors
- Alterity completes Placement Tranche 1 raising $10M
- MSA patients enrolled in bioMUSE Study
- US patent for next generation neurodegenerative diseases
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics